| Literature DB >> 28944074 |
Maria Garrido1, Matteo Turco1, Chiara Formentin1, Michela Corrias1, Michele De Rui1, Sara Montagnese1, Piero Amodio1.
Abstract
BACKGROUND: Providing structured information for the understanding of hepatic encephalopathy (HE) might be relevant to the prevention and management of the syndrome. The aim of our study was to design a brief, structured educational intervention and evaluate its usefulness in preventing HE-related hospitalisation over time.Entities:
Keywords: cirrhosis; education; hepatic encephalopathy; re-admission
Year: 2017 PMID: 28944074 PMCID: PMC5596837 DOI: 10.1136/bmjgast-2017-000161
Source DB: PubMed Journal: BMJ Open Gastroenterol ISSN: 2054-4774
Figure 1Hepatic encephalopathy educational procedure form.
Novel Information Questionnaire
| 1. Are you satisfied with the new information acquired on hepatic encephalopathy? | Yes □ |
| No □ | |
| 1.1. Please mark the correct statements on the causes of hepatic encephalopathy based on the information you have received | The liver does not correctly clean venous blood □ |
| The brain does not receive cleaned arterial blood □ | |
| The brain does not work properly □ | |
| 2. Are you satisfied with the information acquired on the procedures to prevent hepatic encephalopathy? | Yes □ |
| No □ | |
| 2.1. Please mark the correct statements on the prevention and treatment of hepatic encephalopathy based on the information you have received | Two bowel movements per day are necessary □ |
| If less than two bowel movements per day are obtained, you should administer a lactulose enema and/or increase the dose of lactulose/lactitol □ | |
| If more than two bowel movements per day are obtained, you should consider reducing the dose of lactulose/lactitol □ | |
| Non-absorbable antibiotics increase bowel movements □ | |
| Non-absorbable antibiotics reduce the production of toxins in the gut □ | |
| Branched chain amino acids increase bowel movements □ | |
| Branched chain amino acids improve nutrition □ |
Demographic, clinical, neuropsychological and EEG variables by group. No significant differences were observed between groups A and B in any of these variables
| Group A | Group B | |
| Males (%) | 14 (70.0) | 17 (89.4) |
| Age (years) | 64.1±8.8 | 59.4±9.2 |
| Pugh’s score | 7.1±1.3 | 7.1±2.0 |
| Child (%) | ||
| A | 35 | 39 |
| B | 65 | 50 |
| C | 0 | 11 |
| MELD score | 12.7±3.5 | 12.3±3.9 |
| Overt HE* (%) | 15 | 15.8 |
| Aetiology (n (%)) | ||
| Alcohol | 9 (45) | 5 (26) |
| Viral | 8 (40) | 6 (31) |
| Mixed | 2 (10) | 4 (21) |
| Other | 1 (5) | 4 (21) |
| Neuropsychological indices | ||
| MPZS | −0.5±0.7 | −0.6±1.1 |
| PHES-z | −1.7±2.3 | −2.6±4.1 |
| Abnormal PHES (n (%)) | 4 (21)† | 6 (31.5) |
| Sternberg reaction time (ms) | 1713±307 | 1728±472 |
| Sternberg accuracy (%) | 75±23 | 70±17 |
| Sternberg z-score | −1.9±1.4 | −2.1±1.2 |
| Spectral EEG | ||
| MDF (Hz) | 9±1 | 9±2 |
| Delta (%) | 8±5 | 11±12 |
| Theta (%) | 36±19 | 41±16 |
| Alfa (%) | 38±16 | 30±14 |
| Beta (%) | 18±9 | 17±10 |
*Overt HE was graded according to the West Haven criteria (reference 10).
†PHES was not available for one patient.
EEG, electroencephalogram; HE, hepatic encephalopathy; MDF, mean dominant frequency; MELD, Model for End-stage Liver Disease; MPZS, mean psychometric z-score; PHES, Psychometric Hepatic Encephalopathy Score.
Figure 2Cumulative proportion of HE-free patients over time by group (A=intervention; B=no intervention). The risk of HE-related hospitalisation in group A was HR=0.58 (95% CI 0.21 to 1.62; p=0.29). HE, hepatic encephalopathy.
Monovariate analysis showing the association between age, liver function (MELD), abnormal PHES and EEG mean frequency (MDF) with the risk of developing HE-related hospitalisation
| Variables | Beta±SE | p | HR (95% CI) |
| Age | 0.074±0.031 | 0.016 | 1.08 (1.01 to 1.14) |
| MELD | 0.141±0.066 | 0.034 | 1.15 (1.01 to 1.31) |
| Abnormal PHES | 1.035±0.544 | 0.057 | 2.81 (0.97 to 8.17) |
| MDF (EEG) | −0.367±0.155 | 0.017 | 0.69 (0.51 to 0.93) |
EEG, electroencephalogram; HE, hepatic encephalopathy; MDF, mean dominant frequency; MELD, Model for End-stage Liver Disease; PHES, Psychometric Hepatic Encephalopathy Score.